Ezra Klein’s Bill Gates interview frames the case for preventive AI oversight

In an interview with Bill Gates, Ezra Klein questioned why AI companies should not face safeguards comparable to those governing drugmakers, whose products are subject to laws intended to deter releases that could harm many people.

The argument contrasts preventive oversight with relying on lawsuits after damage occurs; one voice in the debate said FDA marketing authorization is effectively necessary to sell and scale a product.